Blog

Melissa’s Race to Battle Brain Cancer

You’ve Been Diagnosed with Cancer. Now What?

June 15, 2021

Media News Stories

Westchester Medical Center First in Region to Offer Brain Tumor Therapy That Can Slow Tumor Progression

July 15, 2021

Media News Stories Physician Interviews

Vidant, ECU Brody School of Medicine Successfully Perform First-in-State GammaTile™ Procedure

January 24, 2020

Patient Navigator
Find a Center
FAQ
Education
Events
Resources
Contact

CONNECT WITH US

TREATMENT CONSIDERATIONS

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS

Blog

Melissa’s Race to Battle Brain Cancer

You may also like:

You’ve Been Diagnosed with Cancer. Now What?

Westchester Medical Center First in Region to Offer Brain Tumor Therapy That Can Slow Tumor Progression

Vidant, ECU Brody School of Medicine Successfully Perform First-in-State GammaTile™ Procedure